吉西他滨联合卡铂治疗晚期卵巢癌的近期疗效

目的评价吉西他滨联合卡铂治疗晚期卵巢癌近期疗效及不良反应。方法选取80例晚期卵巢癌患者,随机分为观察组(40例)和对照组(40例),观察组患者采用吉西他滨联合卡铂治疗,吉西他滨为800 mg/m2,第1、8天,卡铂(AUC5)第1天,静脉用药,3周重复1次,共3个疗程。对照组患者采用卡铂治疗,400mg/m2,静脉滴注,每3周重复治疗1次。3个疗程结束,对肿瘤病灶部位进行CT扫描,根据世界卫生组织实体瘤疗效评价标准对卵巢癌患者的化疗结果进行评价。结果观察组患者治疗后显效16例(40.0%),总有效率为70.0%;对照组患者显效7例(17.5%),总有效率为57.5%,两组间差异有统计学意义(P<0.05)。常见的不良反应为粒细胞减少、血小板减少、疲乏、肌肉酸痛、皮疹和瘙痒等,不良反应较轻,患者可以耐受。结论吉西他滨联合卡铂作为晚期卵巢癌化疗的治疗方案,疗效满意,不良反应轻,值得推广应用。

The curative effect of gemcitabine plus carboplatin in the treatment of advanced ovarian cancer

Objective Evaluation of gemcitabine plus carboplatin in advanced ovarian cancer efficacy and adverse reactions. Methods Select 80 cases of advanced ovarian cancer patients were randomly divided into observation group and control group, the observation group using gemcitabine and carboplatin chemotherapy, gemcitabine 800 mg/m2, day 1,8, carboplatin （AUC5） Section 1 d intravenous drug use, 3 repeated a week, a total of three courses. Control group with carboplatin, 400mg/m2, intravenous drip. Repeated every 3 weeks treatment 1. End of treatment given to three of the tumor lesion site CT scans. According to world health organization response evaluation criteria in solid tumors of ovarian cancer patients with chemotherapy results were evaluated. Results Gemcitabine plus carboplatin treatment group were cured 16 cases （40. 0% ）, total effective rate was 70. 0%, in the control group that were 7 cases （ 17. 5% ）, total efficiency of 57.5%, the difference between the two groups was statistically significant （P 〈0.05）. Common adverse reactions were neutropenia, thrombocytopenia, fatigue, muscle aches, rashes and itching, mild adverse reactions, the patient can tolerate. Conclusions Gemcitabine and carboplatin chemotherapy in advanced ovarian cancer as a treatment program, results were satisfactory, chemotherapy response to light, should be widely applied.